CCO Treatment Updates

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

On-Demand Video Conference

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

CME Program Director: Joseph J. Eron, Jr., MD

Faculty:

Joel E. Gallant, MD, MPH
  • Joel E. Gallant, MD, MPH

CME CREDIT INFORMATION

Release Date: 05/02/06

Expiration Date: 05/01/07


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status
Begin the Webcast

Joel Gallant, MD, presents and discusses the latest data on novel classes of antiretroviral agents and their potential future role in HIV management strategies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the need for novel antiretroviral agents
  • Describe recent data on agents in novel classes, including chemokine coreceptor antagonists and integrase inhibitors
  • Review the clinical settings in which novel antiretroviral agents may find application

CCO Slidesets

Clinical Data and Development of Agents in Novel Antiretroviral Classes


Format: Microsoft PowerPoint (.ppt) | File size: 804 KB


How, Where, and When to Use New Agents


Format: Microsoft PowerPoint (.ppt) | File size: 1.23 MB


Why Do We Need New Antiretroviral Drugs in Novel Classes and How Do They Work?


Format: Microsoft PowerPoint (.ppt) | File size: 1.48 MB


Educational Module

Novel Classes of Antiretrovirals: Update on CCR5 Antagonists and Integrase Inhibitors

CME Program Director: Joseph J. Eron, Jr., MD

Faculty:

Joel E. Gallant, MD, MPH
  • Joel E. Gallant, MD, MPH

CME CREDIT INFORMATION

Release Date: 06/13/06

Expiration Date: 06/12/07


Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

Joel Gallant, MD, reviews the latest data on novel classes of antiretroviral agents and describes how promising new agents may be employed in the treatment of HIV-infected patients in future.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the need for novel antiretroviral agents
  • Describe recent data on agents in novel classes, including chemokine coreceptor antagonists and integrase inhibitors
  • Review the clinical settings in which novel antiretroviral agents may find application
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.